Medpace Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
February 12, 2024 at 04:16 pm EST
Share
Medpace Holdings, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 1,885.84 million compared to USD 1,460 million a year ago. Net income was USD 282.81 million compared to USD 245.37 million a year ago.
Basic earnings per share from continuing operations was USD 9.2 compared to USD 7.57 a year ago. Diluted earnings per share from continuing operations was USD 8.88 compared to USD 7.28 a year ago.
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
MEDPACE HOLDINGS, INC. 
